475 related articles for article (PubMed ID: 25449688)
21. [Relationship between RAD51-g135C and XRCC3-C241T polymorphisms and prognosis of inv (16)/ t(16;16) (CBFbeta-MYH11) acute myeloid leukemia].
Liu L; Yang L; Mi YC; Li JY; Qin TJ; Xu ZF; Zhang Y; Wang JX; Xiao ZJ
Zhonghua Xue Ye Xue Za Zhi; 2011 Jul; 32(7):433-8. PubMed ID: 22213860
[TBL] [Abstract][Full Text] [Related]
22. [Analysis of c-kit and JAK2 gene mutations in t(8;21) acute myeloid leukemia].
Li WY; Sun AN; Wu DP
Zhonghua Xue Ye Xue Za Zhi; 2008 Dec; 29(12):797-801. PubMed ID: 19176031
[TBL] [Abstract][Full Text] [Related]
23. The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia.
Allen C; Hills RK; Lamb K; Evans C; Tinsley S; Sellar R; O'Brien M; Yin JL; Burnett AK; Linch DC; Gale RE
Leukemia; 2013 Sep; 27(9):1891-901. PubMed ID: 23783394
[TBL] [Abstract][Full Text] [Related]
24. [C-kit mutation in acute myeloid leukemia patients with AML1-ETO fusion gene and its clinical significance].
Geng SX; Du X; Weng JY; Huang X; Lu ZS; Zhong LY; Guo R; Wu SJ; Wu P
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Aug; 21(4):839-42. PubMed ID: 23998570
[TBL] [Abstract][Full Text] [Related]
25. Prevalence and prognostic significance of KIT mutations in pediatric patients with core binding factor AML enrolled on serial pediatric cooperative trials for de novo AML.
Pollard JA; Alonzo TA; Gerbing RB; Ho PA; Zeng R; Ravindranath Y; Dahl G; Lacayo NJ; Becton D; Chang M; Weinstein HJ; Hirsch B; Raimondi SC; Heerema NA; Woods WG; Lange BJ; Hurwitz C; Arceci RJ; Radich JP; Bernstein ID; Heinrich MC; Meshinchi S
Blood; 2010 Mar; 115(12):2372-9. PubMed ID: 20056794
[TBL] [Abstract][Full Text] [Related]
26. D816 mutation of the KIT gene in core binding factor acute myeloid leukemia is associated with poorer prognosis than other KIT gene mutations.
Yui S; Kurosawa S; Yamaguchi H; Kanamori H; Ueki T; Uoshima N; Mizuno I; Shono K; Usuki K; Chiba S; Nakamura Y; Yanada M; Kanda J; Tajika K; Gomi S; Fukunaga K; Wakita S; Ryotokuji T; Fukuda T; Inokuchi K
Ann Hematol; 2017 Oct; 96(10):1641-1652. PubMed ID: 28762080
[TBL] [Abstract][Full Text] [Related]
27. Immunophenotypic profile predictive of KIT activating mutations in AML1-ETO leukemia.
De J; Zanjani R; Hibbard M; Davis BH
Am J Clin Pathol; 2007 Oct; 128(4):550-7. PubMed ID: 17875504
[TBL] [Abstract][Full Text] [Related]
28. KIT mutations correlate with adverse survival in children with core-binding factor acute myeloid leukemia.
Chen X; Dou H; Wang X; Huang Y; Lu L; Bin J; Su Y; Zou L; Yu J; Bao L
Leuk Lymphoma; 2018 Apr; 59(4):829-836. PubMed ID: 28792268
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Importance of C-KIT Mutations in Core Binding Factor Acute Myeloid Leukemia: A Systematic Review.
Ayatollahi H; Shajiei A; Sadeghian MH; Sheikhi M; Yazdandoust E; Ghazanfarpour M; Shams SF; Shakeri S
Hematol Oncol Stem Cell Ther; 2017 Mar; 10(1):1-7. PubMed ID: 27613372
[TBL] [Abstract][Full Text] [Related]
30. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia.
Lugthart S; Gröschel S; Beverloo HB; Kayser S; Valk PJ; van Zelderen-Bhola SL; Jan Ossenkoppele G; Vellenga E; van den Berg-de Ruiter E; Schanz U; Verhoef G; Vandenberghe P; Ferrant A; Köhne CH; Pfreundschuh M; Horst HA; Koller E; von Lilienfeld-Toal M; Bentz M; Ganser A; Schlegelberger B; Jotterand M; Krauter J; Pabst T; Theobald M; Schlenk RF; Delwel R; Döhner K; Löwenberg B; Döhner H
J Clin Oncol; 2010 Aug; 28(24):3890-8. PubMed ID: 20660833
[TBL] [Abstract][Full Text] [Related]
31. A genome-wide single-nucleotide polymorphism-array can improve the prognostic stratification of the core binding factor acute myeloid leukemia.
Huh J; Kim HJ; Jung CW; Kim HJ; Kim SH; Kim YK; Kim HJ; Shin MG; Moon JH; Sohn SK; Kim SH; Lee WS; Won JH; Mun YC; Kim H; Park J; Min WS; Kim DH;
Am J Hematol; 2012 Oct; 87(10):961-8. PubMed ID: 22886749
[TBL] [Abstract][Full Text] [Related]
32. Cooperating mutations of receptor tyrosine kinases and Ras genes in childhood core-binding factor acute myeloid leukemia and a comparative analysis on paired diagnosis and relapse samples.
Shih LY; Liang DC; Huang CF; Chang YT; Lai CL; Lin TH; Yang CP; Hung IJ; Liu HC; Jaing TH; Wang LY; Yeh TC
Leukemia; 2008 Feb; 22(2):303-7. PubMed ID: 17960171
[TBL] [Abstract][Full Text] [Related]
33. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias.
Krauter J; Gorlich K; Ottmann O; Lubbert M; Dohner H; Heit W; Kanz L; Ganser A; Heil G
J Clin Oncol; 2003 Dec; 21(23):4413-22. PubMed ID: 14645432
[TBL] [Abstract][Full Text] [Related]
34. Incidences and Prognostic Impact of c-KIT, WT1, CEBPA, and CBL Mutations, and Mutations Associated With Epigenetic Modification in Core Binding Factor Acute Myeloid Leukemia: A Multicenter Study in a Korean Population.
Park SH; Lee HJ; Kim IS; Kang JE; Lee EY; Kim HJ; Kim YK; Won JH; Bang SM; Kim H; Song MK; Chung JS; Shin HJ
Ann Lab Med; 2015 May; 35(3):288-97. PubMed ID: 25932436
[TBL] [Abstract][Full Text] [Related]
35. ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.
Yamato G; Shiba N; Yoshida K; Shiraishi Y; Hara Y; Ohki K; Okubo J; Okuno H; Chiba K; Tanaka H; Kinoshita A; Moritake H; Kiyokawa N; Tomizawa D; Park MJ; Sotomatsu M; Taga T; Adachi S; Tawa A; Horibe K; Arakawa H; Miyano S; Ogawa S; Hayashi Y
Genes Chromosomes Cancer; 2017 May; 56(5):382-393. PubMed ID: 28063196
[TBL] [Abstract][Full Text] [Related]
36. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
[TBL] [Abstract][Full Text] [Related]
37. Dual color FISH on CBF primary acute myeloid leukemia.
Sorour A; Nafea D
Egypt J Immunol; 2008; 15(2):25-31. PubMed ID: 20306685
[TBL] [Abstract][Full Text] [Related]
38. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
39. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)].
Perea G; Lasa A; Aventín A; Domingo A; Villamor N; Queipo de Llano MP; Llorente A; Juncà J; Palacios C; Fernández C; Gallart M; Font L; Tormo M; Florensa L; Bargay J; Martí JM; Vivancos P; Torres P; Berlanga JJ; Badell I; Brunet S; Sierra J; Nomdedéu JF;
Leukemia; 2006 Jan; 20(1):87-94. PubMed ID: 16281071
[TBL] [Abstract][Full Text] [Related]
40. Complex karyotype, older age, and reduced first-line dose intensity determine poor survival in core binding factor acute myeloid leukemia patients with long-term follow-up.
Mosna F; Papayannidis C; Martinelli G; Di Bona E; Bonalumi A; Tecchio C; Candoni A; Capelli D; Piccin A; Forghieri F; Bigazzi C; Visani G; Zambello R; Zanatta L; Volpato F; Paolini S; Testoni N; Gherlinzoni F; Gottardi M
Am J Hematol; 2015 Jun; 90(6):515-23. PubMed ID: 25753065
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
